Clinical trial
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or…
NCT00343720 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00343720 |
|---|---|
| Title | Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy |
| Official title | A Randomized, Open-Label, Multicenter Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | VELCADE, Alimta |
| Primary completion | Oct 1, 2007 |
| First posted | Jun 23, 2006 |
| Last update posted | Mar 13, 2008 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: